Why Pilots Don’t Scale: The Case for Pre-Protocol Invariants in Clinical Development
A leading sponsor hit 79% site adoption and called it a ceiling. The fix isn’t better tools—it’s pre-protocol invariants...
Clinical Operations
When Your CRO Gets Acquired Mid-Trial, the Site Pays the Operational Price
Tevogen Bio's MSO/CRO acquisition push signals a consolidation wave that will disrupt site activation, monitoring, and contracts mid-study. Here's...
When the Manufacturing Site Fails, Your Enrollment Plan Fails With It
Novo Nordisk's Bloomington facility hit with another FDA 483 — here's how manufacturing findings cascade into site enrollment holds,...
When AI Picks Your Site, Execution Still Happens in the Building
ASCO and Ryght AI are using machine learning to select breast cancer trial sites. Here's what that means for...
When Your CRO’s Books Were Wrong, Your Trial Budget Probably Was Too
ICON's $158M revenue restatement across 2023–2024 exposes how CRO accounting gaps cascade into site payment delays, contract disputes, and...
Veeva Unveils Falcon AI Platform and Agentic Authoring at 2026 Summit
At the 2026 Veeva R&D and Quality Summit in Copenhagen, Veeva Systems announced three major AI capabilities: Vault AI,...
When AI Scales Your Protocol, It Scales Every Flaw Inside It
Phesi's 2026 analysis found fewer than 1 in 3 trial protocols are linked to patient data—meaning AI tools are...
The FDA’s One-Day Inspection Pilot Will Expose Every Site That Built Readiness for a Five-Day Visit
FDA's April 2026 one-day inspection pilot compresses what sites have 5 days to prove into a single visit—here's what...
When Gilead Cuts 108 Jobs at Arcellx, Your Trial Feels It Before You Know Why
Gilead's $7.8B Arcellx acquisition just cut 108 Redwood City jobs. Here's what that means for CAR-T trial sites running...
The Protocol Complexity Tax: What Sponsors Don’t See on the Site Invoice
Protocol complexity now drives 76% of trials to at least one amendment—here's what that costs sites in activation days,...